Literature DB >> 12461058

Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.

A J Rice1, M A Steward, C M Quinn.   

Abstract

AIM: Angiogenesis plays an important role in tumour growth and has been shown to occur around both in situ and invasive tumours. The degree of angiogenesis within tumours depends on the balance of pro-angiogenic and anti-angiogenic factors. One such anti-angiogenic factor is thrombospondin 1 (TSP-1). This study investigates the pattern of expression of TSP-1 in ductal carcinoma in situ (DCIS) of the breast and its relation to the surrounding microvessel pattern and density. MATERIALS/
METHODS: The expression of TSP-1 was studied in formalin fixed, paraffin wax embedded sections from 58 cases of pure DCIS, using a monoclonal antibody against TSP-1 and the avidin-biotin-diaminobenzidine immunoperoxidase detection system. Vessels were stained with a monoclonal antibody to the endothelial cell marker CD31. Stromal microvessel density was assessed by counting "hot spots" within 500 micro m of the basement membrane of involved ducts using a 25 point Chalkey graticule.
RESULTS: TSP-1 staining of the basement membrane around duct spaces with DCIS was seen in 69% of cases. In addition, staining of the stroma between involved duct spaces was seen in 31% of cases, with a fibrillary pattern identical to that seen in invasive breast carcinomas. In 12% of cases no staining for TSP-1 was seen. Two patterns of vascularity were identified. A cuff of vessels immediately adjacent to the basement membrane of ducts with DCIS was seen in 71% of cases. The presence of stromal TSP-1 was significantly associated with DCIS showing no/little necrosis (p = 0.01) and no/little periductal inflammation (p = 0.04). There was a trend between the presence of stromal TSP-1 and tumour cell negativity for p53 (p = 0.087). The stromal microvessel Chalkey point count ranged between 3.33 and 16. An increased stromal microvessel count was associated with high histological grade (p = 0.02), extensive necrosis (p = 0.047), and pronounced periductal inflammation (p = 0.049). There was no association between the presence of stromal TSP-1 and stromal microvessel density.
CONCLUSIONS: TSP-1 is expressed in the stroma around DCIS and in the immediately adjacent basement membrane. Expression of stromal TSP-1 is lost in DCIS with more aggressive histological features. The absence of a relation with microvessel density suggests that other angiogenic factors may play an important role in DCIS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12461058      PMCID: PMC1769827          DOI: 10.1136/jcp.55.12.921

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  42 in total

1.  Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast.

Authors:  A H Lee; E A Dublin; L G Bobrow
Journal:  J Pathol       Date:  1999-02       Impact factor: 7.996

Review 2.  Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast.

Authors:  A Rice; C M Quinn
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

3.  Transforming growth factor-beta complexes with thrombospondin.

Authors:  J E Murphy-Ullrich; S Schultz-Cherry; M Höök
Journal:  Mol Biol Cell       Date:  1992-02       Impact factor: 4.138

4.  Angiogenic growth factors in preinvasive breast disease.

Authors:  S C Heffelfinger; M A Miller; R Yassin; R Gear
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

5.  Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.

Authors:  R Bos; H Zhong; C F Hanrahan; E C Mommers; G L Semenza; H M Pinedo; M D Abeloff; J W Simons; P J van Diest; E van der Wall
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

Review 6.  Angiogenesis in cancer and other diseases.

Authors:  P Carmeliet; R K Jain
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

7.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.

Authors:  N Weidner; J P Semple; W R Welch; J Folkman
Journal:  N Engl J Med       Date:  1991-01-03       Impact factor: 91.245

8.  Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder.

Authors:  G W Chodak; C Haudenschild; R F Gittes; J Folkman
Journal:  Ann Surg       Date:  1980-12       Impact factor: 12.969

9.  Thrombospondin modulates focal adhesions in endothelial cells.

Authors:  J E Murphy-Ullrich; M Höök
Journal:  J Cell Biol       Date:  1989-09       Impact factor: 10.539

10.  Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor.

Authors:  G Taraboletti; D Roberts; L A Liotta; R Giavazzi
Journal:  J Cell Biol       Date:  1990-08       Impact factor: 10.539

View more
  8 in total

1.  Regulation of VEGF-A, VEGFR-I, thrombospondin-1, -2, and -3 expression in a human pituitary cell line (HP75) by TGFbeta1, bFGF, and EGF.

Authors:  Hidehisa Horiguchi; Long Jin; Katharina H Ruebel; Bernd W Scheithauer; Ricardo V Lloyd
Journal:  Endocrine       Date:  2004-07       Impact factor: 3.633

2.  THBS1 (thrombospondin-1).

Authors:  Jeffrey S Isenberg; David D Roberts
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2020

Review 3.  Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies.

Authors:  Jeff S Isenberg; Gema Martin-Manso; Justin B Maxhimer; David D Roberts
Journal:  Nat Rev Cancer       Date:  2009-02-05       Impact factor: 60.716

4.  Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan; Vincenzo Costigliola; Daniela Trog; Michael Braun; Manuel Debald; Walther Kuhn; Hans H Schild
Journal:  EPMA J       Date:  2013-02-19       Impact factor: 6.543

Review 5.  Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.

Authors:  Yasuyoshi Miyata; Hideki Sakai
Journal:  Int J Mol Sci       Date:  2013-06-07       Impact factor: 5.923

6.  Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.

Authors:  Seung-Beom Hong; HyoungBin Oh; Vladimir A Valera; Jaime Stull; Duy-Tan Ngo; Masaya Baba; Maria J Merino; W Marston Linehan; Laura S Schmidt
Journal:  Mol Cancer       Date:  2010-06-23       Impact factor: 27.401

7.  Thrombospondin-1 and VEGF in inflammatory bowel disease.

Authors:  Canan Alkim; Damlanur Sakiz; Huseyin Alkim; Ayten Livaoglu; Tulin Kendir; Huseyin Demirsoy; Levent Erdem; Nihat Akbayir; Mehmet Sokmen
Journal:  Libyan J Med       Date:  2012-01-30       Impact factor: 1.657

8.  Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.

Authors:  Jessica Wang-Rodriguez; Virginia Urquidi; Amber Rivard; Steve Goodison
Journal:  Breast Cancer Res       Date:  2003-07-09       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.